Improving IBD diagnosis and monitoring by understanding preanalytical, analytical and biological fecal calprotectin variability

Clinical Chemistry and Laboratory Medicine

Volumn 56, Issue 11, 2018, Pages 1926-1935

  Padoan, Andrea ^a   D'Incà, Renata ^b   Scapellato, Maria Luisa ^b   De Bastiani, Rudi ^c   Caccaro, Roberta ^b   Mescoli, Claudia ^a   Moz, Stefania ^a   Bozzato, Dania ^a   Zambon, Carlo Federico ^a   Lorenzon, Greta ^b   Rugge, Massimo ^a   Plebani, Mario ^a   Basso, Daniela ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^c Italian Association for Gastroenterology in Primary Care (GICA CP)   (Italy)

Author keywords

biological variability; calprotectin; Crohn's disease; inflammatory bowel diseases; ulcerative colitis

Indexed keywords

ANTIBODY; CALGRANULIN;

ACCURACY; ADULT; AGED; ARTICLE; CASE CONTROL STUDY; CHEMILUMINESCENCE IMMUNOASSAY; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FECES; FEMALE; HUMAN; IMMUNOTURBIDIMETRY; INFLAMMATORY BOWEL DISEASE; INTERMETHOD COMPARISON; LIMIT OF DETECTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; REFERENCE VALUE; SENSITIVITY AND SPECIFICITY; ADOLESCENT; AREA UNDER THE CURVE; CHEMISTRY; PHOTOMETRY; PRE-ANALYTICAL PHASE; PROCEDURES; REPRODUCIBILITY; STANDARDS; YOUNG ADULT;

ADOLESCENT; AGED; AREA UNDER CURVE; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FECES; FEMALE; HUMANS; INFLAMMATORY BOWEL DISEASES; LEUKOCYTE L1 ANTIGEN COMPLEX; MALE; MIDDLE AGED; NEPHELOMETRY AND TURBIDIMETRY; PRE-ANALYTICAL PHASE; REFERENCE VALUES; REPRODUCIBILITY OF RESULTS; ROC CURVE; SENSITIVITY AND SPECIFICITY; YOUNG ADULT;

EID: 85046964140     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm-2018-0134     Document Type: Article

References (37)

1. Mowat C, Cole A, Windsor A, Ahmad T, Arnott I, Driscoll R, et al. Guidelines for the management of inflammatory bowel disease in adults. Gut 2011;60:571-607.
2. Sands BE. Biomarkers of inflammation in inflammatory bowel disease. Gastroenterology 2015;149:1275-85. e2.
3. Reese GE, Constantinides VA, Simillis C, Darzi AW, Orchard TR, Fazio VW, et al. Diagnostic precision of anti-Saccharomyces cerevisiae antibodies and perinuclear antineutrophil cytoplasmic antibodies in inflammatory bowel disease. Am J Gastroenterol 2006;101:2410-22.
4. Fengming Y, Jianbing W. Biomarkers of inflammatory bowel disease. Dis Markers 2014;2014:710915.
5. Menees SB, Powell C, Kurlander J, Goel A, Chey WD. A metaanalysis of the utility of C-reactive protein, erythrocyte sedimentation rate, fecal calprotectin, and fecal lactoferrin to exclude inflammatory bowel disease in adults with IBS. Am J Gastroenterol 2015;110:444-54.
6. Lin J-F, Chen J-M, Zuo J-H, Yu A, Xiao ZJ, Deng FH, et al. Metaanalysis: fecal calprotectin for assessment of inflammatory bowel disease activity. Inflamm Bowel Dis 2014;20:1407-15.
7. Waugh N, Cummins E, Royle P, Kandala NB, Shyangdan D, Arasaradnam R, et al. Faecal calprotectin testing for differentiating amongst inflammatory and non-inflammatory bowel diseases: systematic review and economic evaluation. Health Technol Assess 2013;17:xv-xix-1-211. [Epub ahead of print] 24286461.
8. Kok L, Elias SG, Witteman BJ, Goedhard JG, Muris JW, Moons KG, et al. Diagnostic accuracy of point-of-care fecal calprotectin and immunochemical occult blood tests for diagnosis of organic bowel disease in primary care: the cost-effectiveness of a decision rule for abdominal complaints in primary care (CEDAR) study. Clin Chem 2012;58:989-98.
9. Zubin G, Peter L. Predicting endoscopic Crohn's disease activity before and after induction therapy in children: a comprehensive assessment of PCDAI, CRP, and fecal calprotectin. Inflamm Bowel Dis 2015;21:1386-91.
10. Louis E, Mary JY, Massouille GV, Grimaud JC, Bouhnik Y, Laharie D, et al. Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after Infliximab therapy is stopped. Gastroenterology 2012;142:63-70. e5.
11. D'Inca R, Caccaro R. Measuring disease activity in Crohn's disease: what is currently available to the clinician. Clin Exp Gastroenterol 2014;7:151-61.
12. Boschetti G, Garnero P, Moussata D, Cuerq C, Preaudat C, Duclaux-Loras R, et al. Accuracies of serum and fecal S100 proteins (calprotectin and calgranulin C) to predict the response to TNF antagonists in patients with Crohn's disease. Inflamm Bowel Dis 2015;21:331-6.
13. Whitehead SJ, French J, Brookes MJ, Ford C, Gama R. Betweenassay variability of faecal calprotectin enzyme-linked immunosorbent assay kits. Ann Clin Biochem 2013;50:53-61.
14. Lasson A, Stotzer P-O, Ohman L, Isaksson S, Sapnara M, Strid H. The intra-individual variability of faecal calprotectin: a prospective study in patients with active ulcerative colitis. J Crohns Colitis 2015;9:26-32.
15. Roseth AG, Fagerhol MK, Aadland E, Schjonsby H. Assessment of the neutrophil dominating protein calprotectin in feces. A methodologic study. Scand J Gastroenterol 1992;27:793-8.
16. Husebye E, Ton H, Johne B. Biological variability of fecal calprotectin in patients referred for colonoscopy without colonic inflammation or neoplasm. Am J Gastroenterol 2001;96:2683-7.
17. Du L, Foshaug R, Huang VW, Kroeker KI, Dieleman LA, Halloran BP, et al. Within-stool and within-day sample variability of fecal calprotectin in patients with inflammatory bowel disease: a prospective observational study. J Clin Gastroenterol 2018;52:235-40.
18. Calafat M, Cabre E, Manosa M, Lobaton T, Marin L, Domenech E. High within-day variability of fecal calprotectin levels in patients with active ulcerative colitis: what is the best timing for stool sampling? Inflamm Bowel Dis 2015;21:1072-6.
19. Plebani M. What information on quality specifications should be communicated to clinicians, and how? Clin Chim Acta 2004;346:25-35.
20. De Sloovere MM, De Smet D, Baert FJ, Debrabandere J, Vanpoucke HJ. Analytical and diagnostic performance of two automated fecal calprotectin immunoassays for detection of inflammatory bowel disease. Clin Chem Lab Med 2017;55:1435-46.
21. Kittanakom S, Shajib MS, Garvie K, Turner J, Brooks D, Odeh S, et al. Comparison of fecal calprotectin methods for predicting relapse of pediatric inflammatory bowel disease. Can J Gastroenterol Hepatol 2017;2017:1450970.
22. Clinical and Laboratory Standards Institute (CLSI). User verification of precision and estimation of bias; Approved Guideline-Third Edition. CLSI EP15, Wayne, PA, USA, 2014.
23. Fraser CG, Harris EK. Generation and application of data on biological variation in clinical chemistry. Crit Rev Clin Lab Sci 1989;27:409-37.
24. van Deen WK, van Oijen MG, Myers KD, Centeno A, Howard W, Choi JM, et al. A nationwide 2010-2012 analysis of U. S. health care utilization in inflammatory bowel diseases. Inflamm Bowel Dis 2014;20:1747-53.
25. Ferreiro-Iglesias R, Barreiro-de Acosta M, Lorenzo-Gonzalez A, Dominguez-Munoz JE. Accuracy of consecutive fecal calprotectin measurements to predict relapse in inflammatory bowel disease patients under maintenance with anti-TNF therapy: a prospective longitudinal cohort study. J Clin Gastroenterol 2018;52:229-34.
26. Heida A, Park KT, van Rheenen PF. Clinical utility of fecal calprotectin monitoring in asymptomatic patients with inflammatory bowel disease: a systematic review and practical guide. Inflamm Bowel Dis 2017;23:894-902.
27. Pavlidis P, Chedgy FJ, Tibble JA. Diagnostic accuracy and clinical application of faecal calprotectin in adult patients presenting with gastrointestinal symptoms in primary care. Scand J Gastroenterol 2013;48:1048-54.
28. Schoepfer AM, Lewis JD. Serial fecal calprotectin measurements to detect endoscopic recurrence in postoperative Crohn's disease: is colonoscopic surveillance no longer needed? Gastroenterology 2015;148:889-92.
29. Bjarnason I. The use of fecal calprotectin in inflammatory bowel disease. Gastroenterol Hepatol (N Y) 2017;13:53-6.
30. Dumoulin EN, Van Biervliet S, Langlois MR, Delanghe JR. Proteolysis is a confounding factor in the interpretation of faecal calprotectin. Clin Chem Lab Med 2015;53:65-71.
31. Hayden JA, Brophy MB, Cunden LS, Nolan EM. High-affinity manganese coordination by human calprotectin is calciumdependent and requires the histidine-rich site formed at the dimer interface. J Am Chem Soc 2013;135:775-87.
32. Annahazi A, Molnar T, Farkas K, Rosztoczy A, Izbeki F, Gecse K, et al. Fecal MMP-9: a new noninvasive differential diagnostic and activity marker in ulcerative colitis. Inflamm Bowel Dis 2013;19:316-20.
33. Farkas K, Sarodi Z, Balint A, Foldesi I, Tiszlavicz L, Sz?cs M, et al. The diagnostic value of a new fecal marker, matrix metalloprotease-9, in different types of inflammatory bowel diseases. J Crohns Colitis 2015;9:231-7.
34. Farkas K, Balint A, Bor R, Foldesi I, Sz?cs M, Nagy F, et al. Faecal matrix metalloprotease-9 is a more sensitive marker for diagnosing pouchitis than faecal calprotectin: results from a pilot study. Expert Rev Gastroenterol Hepatol 2015;9: 387-92.
35. Moz S, Basso D, Padoan A, Bozzato D, Fogar P, Zambon CF, et al. Blood expression of matrix metalloproteinases 8 and 9 and of their inducers S100A8 and S100A9 supports diagnosis and prognosis of PDAC-associated diabetes mellitus. Clin Chim Acta 2016;456:24-30.
36. Basso D, Bozzato D, Padoan A, Moz S, Zambon CF, Fogar P, et al. Inflammation and pancreatic cancer: molecular and functional interactions between S100A8, S100A9, NT-S100A8 and TGF?1. Cell Commun Signal 2014;12:20.
37. Joshi S, Lewis SJ, Creanor S, Ayling RM. Age-related faecal calprotectin, lactoferrin and tumour M2-PK concentrations in healthy volunteers. Ann Clin Biochem 2010;47:259-63.